ACC 2026: Sotatercept shows signal in CpcPH-HFpEF at lower dose
At ACC 2026, the phase II CADENCE trial reported results for sotatercept (WINREVAIR) in adults with combined post- and precapillary pulmonary hypertension associated with HFpEF.
Read the full article on the original site.
Read Full Article